Abstract
The paper analyzes modern views on the etiology, epidemiology, pathogenesis, methods of treating patients with chronic viral hepatitis C with concomitant non-alcoholic fatty liver disease (NAFLD), discusses the possibility of using "dry" carbon dioxide baths (DCDB) in this category of patients. Our research was conducted to study the effectiveness of the integrated use of antiviral therapy (AVT) and DCDB procedures in patients with chronic hepatitis C with concomitant NAFLD. The authors of the study were the first to suggest using of DCDB in this category of patients. Based on the results obtained, for the first time, ideas about the specificity of the DCDBʹs effect on the clinical course of the underlying and concomitant diseases, on the functional state of the liver, the dynamics of lipid metabolism, and ultrasonographic parameters of the liver were detailed. It is concluded that DCDB can be successfully used in the complex treatment of patients with chronic hepatitis C with concomitant NAFLD.
Highlights
Liver disease is a major cause of disability and mortality worldwide
The treatment in both groups was accompanied by a positive dynamics of most signs of the disease, a detailed analysis revealed significant benefits in patients of group 2 with the use of Dry carbonic acid gas bath (DCAGB)
In patients of group 2, a probable decrease in the manifestations of asthenic (p
Summary
According to WHO expert estimates, the prevalence of HCV infection in the general population is 3%, 3-4 million people are infected with hepatitis C virus annually. Ukraine, according to the WHO, is one of the countries with a moderate prevalence of HCV infection, affecting from 1 to 2,5% of the population. It is known that patients with chronic hepatitis C (CHC) are at high risk of liver cirrhosis and hepatocellular carcinoma. Cirrhosis of the liver develops in 10-20% of patients with CHC and is usually detected 10-20 years after the onset of the disease. Infection with hepatitis C virus increases the risk of hepatocellular carcinoma by 11 times. Annual mortality in patients with hepatocellular carcinoma increases to 80-90% in economically developed and developing countries, respectively [5, 6]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
